RxDoctor Payments Data

Marius Gradianu, DO

Ophthalmology · Elmhurst, ILNPI 1144665878

Payments from drug & device makers

$41,638in general payments, 2019–2025

Across 645 payments — averaging $64.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$6K
  • Carl Zeiss Meditec USA, Inc.$5K
  • Bausch & Lomb Americas Inc.$5K
  • Johnson & Johnson Surgical Vision, Inc.$4K
  • AbbVie$3K
  • Biotissue Holdings Inc.$2K
  • plus $16K from 37 others

What the payments were for

  • Consulting fees$6902%
  • Travel & lodging$6,09715%
  • Food & beverage$30,58173%
  • Entertainment$380%
  • Other$4,23210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,638 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$360,128
Medicare patients
581
Services billed
3,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast34$45,269
CequaCyclosporine36$37,189
LumiganBimatoprost61$33,417
VevyeCyclosporine32$27,880
RestasisCyclosporine26$26,807
Prednisolone Acetate519$22,846
XdemvyLotilaner12$22,291
RocklatanNetarsudil Mesylat/Latanoprost35$15,970
ProlensaBromfenac Sodium17$7,342
Difluprednate51$6,939
MoxifloxacinMoxifloxacin Hcl302$5,778
Ketorolac Tromethamine336$5,322
RhopressaNetarsudil Mesylate13$5,235
VyzultaLatanoprostene Bunod11$4,794
Bromfenac Sodium21$3,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$2,746$60,22487 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$4,813$50,06345 claims
Sun Pharmaceutical Industries Inc.Cequa$1,312$37,18936 claims
Harrow Eye, LLCVevye$390$27,88032 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$338$22,29112 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$27$21,20548 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$1,964$7,34217 claims
AlconSimbrinza$2,299$3,57318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →